Nasdaq

Nexstim Plc Files 510(k) Submission for its NBT® system for the Treatment of Depression with US FDA

27-06-2017


Company announcement, Helsinki, 27 June 2017 at 9 am


Nexstim Plc Files 510(k) Submission for its
NBT® system for the

Treatment
of Depression with US FDA

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("
Nexstim
" or "
Company
"), a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic applications, is pleased to announce it filed a 510(k) submission for its NBT® system for the treatment of Major Depressive Disorder (MDD) with the US FDA on June 26, 2017.

MDD is a recurrent and frequently chronic disorder affecting 2-5% of the population in developed countries. Current treatment options involving pharmacologic agents and psychotherapy are sub-optimal, with 20-40% of patients gaining insufficient benefit. Neuro-stimulation, by repetitive Transcranial Magnetic Stimulation (TMS) has been shown to be effective in treating depression in patients who have failed pharmacologic treatment.

 
Commenting on the submission, Martin Jamieson, Chairman and CEO, Nexstim Plc stated:
"This planned 510(k) submission for the treatment of depression is a further major milestone as we execute our strategy, which is centred on building a significant business for our NBT® system in the US. We are looking forward to being in a position to market our NBT® system for depression, an indication where current treatment options are sub-optimal, starting early in 2018."

NEXSTIM PLC


Martin Jamieson, Chairman and CEO

Further information is available on the website
www.nexstim.com
or by telephone:

Nexstim
                                                                      +447715163942


Martin Jamieson, Chairman and CEO                                               martin.jamieson@nexstim.com


                                                                                                                                                      


UB Securities Oy
(Certified Adviser)                                                                   +358 (0)9 2538 0246

Citigate Dewe Rogerson
                                   +44 (0)207 2822949


David Dible                                                                                             david.dible@citigatedr.co.uk

About Nexstim Plc


Nexstim is a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim's NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain.

Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked for the treatment of stroke, major depression and chronic neuropathic pain. The NBT® system is currently in a supplemental Phase III study, E-FIT trial, which will recruit 60 patients. The trial is expected to complete in Q2 2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.

Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Nexstim Oyj via GlobeNewswire

HUG#2115594

Interstitiel mediset